Inogen, Inc.
NASDAQ:INGNMedical - Devices
+$0.05 today
- Market cap
- $144.83M
- Beta
- 1.59
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.91
Volume 0.19M
Average 0.33M
INGN Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Inogen, Inc.NASDAQ: INGN
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items growth accelerates
Q1 FY2026 other non-cash items of $3.07M rose 6.9% year over year, ahead of the -38.5% change in trailing-twelve-month other non-cash items. Sequentially, it rose 36.6% from the prior quarter. Over 3 fiscal years it compounded at -41.8% a year.
Context
- Other non-cash items amounted to 3.1% of revenue in FY2025, down 2.5 pp from a year earlier.
- Other non-cash items increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +6.9% holds above the trailing-twelve-month pace of -38.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 10.87M USD
- Year-over-year change
- -42.6%
- 4-year CAGR
- +37.8%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.87M | -42.6% |
| FY2024 | 2024-12-31 | 18.94M | -68.2% |
| FY2023 | 2023-12-31 | 59.62M | +8.1% |
| FY2022 | 2022-12-31 | 55.16M | +1729.0% |
| FY2021 | 2021-12-31 | 3.02M | — |
Other Non-Cash Items vs competitors
How INGN compares with its peers on the latest reported figures
- INGN's LTM Mar 2026 other non-cash items of $11.07M is the 5th largest of the 11 companies compared; the peer median is $8.53M.
- Its year-over-year change of -38.5% is the 7th highest of 10, against a peer median of +147.8%.
- Other non-cash items amounts to 3.1% of revenue for INGN, versus a peer median of 19.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $215.76M | +13309.8% | +795.2% | 71.3% | |
| LTM Mar 2026 | $109.56M | +9602.3% | +165.2% | 1142.6% | |
| LTM Mar 2026 | $27.95M | +210.6% | — | 19.3% | |
| LTM Dec 2025 | $16.35M | +84.5% | -30.6% | 125.6% | |
| LTM Mar 2026 | $11.07M | -38.5% | -41.8% | 3.1% | |
| LTM Mar 2026 | $9.73M | -57.7% | +151.8% | 1574.8% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $7.32M | +1998.8% | +92.4% | — |
| LTM Mar 2026 | $6.22M | +147.8% | +30.0% | 5.3% | |
| LTM Mar 2026 | $5.22M | -85.4% | -8.1% | 11.8% | |
| LTM Mar 2026 | $1.81M | — | — | 3.3% | |
| LTM Mar 2026 | $834K | -92.4% | -11.7% | 1.0% | |
| Peer median (excluding INGN) | $8.53M | +147.8% | +61.2% | 19.3% | |
Competitors are the stored peer set for INGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.33M) | (83.77M) | (102.45M) | (35.89M) | (22.75M) |
| Depreciation & Amortization | 21.63M | 23.51M | 18.15M | 21M | 20.66M |
| Deferred Income Tax | 14.44M | 0 | (251K) | (1.15M) | (1.1M) |
| Stock-Based Compensation | 10.94M | 12.28M | 7.43M | 7.4M | 8.01M |
| Change in Working Capital | (20.07M) | (44.72M) | 14.27M | (4.39M) | (26.91M) |
| Accounts Receivables | (5.42M) | (51.62M) | 11.13M | (5.07M) | (14.62M) |
| Inventory | (10.78M) | (5.6M) | 7.88M | (3.54M) | (3.21M) |
| Accounts Payables | (6.48M) | 6.76M | (9.18M) | (3.41M) | 5.6M |
| Other Working Capital | 2.61M | 5.74M | 4.44M | 7.63M | (14.68M) |
| Other Non-Cash Items | 3.02M | 55.16M | 59.62M | 18.94M | 10.87M |
| Operating Cash Flow | 23.63M | (37.53M) | (3.23M) | 5.91M | (11.22M) |
| Capital Expenditures | (23.94M) | (21.22M) | (26.52M) | (17.09M) | (10.38M) |
| Acquisitions (Net) | 153K | 331K | (29.44M) | 0 | 0 |
| Purchases of Investments | (9.99M) | 0 | (26.87M) | (32.66M) | (29.83M) |
| Sales of Investments | 19.26M | 10.01M | 24M | 35.5M | 14M |
| Other Investing Activities | 0 | 0 | 0 | (1.82M) | 0 |
| Investing Cash Flow | (14.65M) | (10.88M) | (59.32M) | (13.98M) | (26.21M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.65M | 1.74M | 1.48M | 811K | 28.18M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (647K) | (1.36M) | (518K) | (546K) | (4M) |
| Financing Cash Flow | 15M | 380K | 960K | 265K | 24.18M |
| Effect of Forex Changes | (426K) | (481K) | 67K | (281K) | 846K |
| Net Change in Cash | 23.56M | (48.51M) | (61.52M) | (8.08M) | (12.4M) |
| Free Cash Flow | (302K) | (58.75M) | (29.75M) | (11.18M) | (21.6M) |
Inogen, Inc.
NASDAQ:INGN
Intrinsic Alpha fair value
Locked
Current Price
$5.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.